Clinical Trial Update: Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fludarabine plus alemtuzumab versus fludarabine alone in chronic lymphocytic leukemia; results completed and posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• Fludara (fludarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: B-Cell Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2011-08-11